248 related articles for article (PubMed ID: 8239673)
21. Neuropharmacology of emesis in relation to clinical response.
Costall B; Naylor RJ
Br J Cancer Suppl; 1992 Dec; 19():S2-7; discussion S7-8. PubMed ID: 1467196
[TBL] [Abstract][Full Text] [Related]
22. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
Tyers MB
Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
[TBL] [Abstract][Full Text] [Related]
23. 5-HT activates vagal afferent cell bodies in vivo: role of 5-HT2 and 5-HT3 receptors.
Lacolley P; Owen JR; Sandock K; Lewis TH; Bates JN; Robertson TP; Lewis SJ
Neuroscience; 2006 Nov; 143(1):273-87. PubMed ID: 17029799
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
Bremerkamp M
Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
[TBL] [Abstract][Full Text] [Related]
25. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
26. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
27. Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
Martin C; Roman V; Agay D; Fatôme M
Radiat Res; 1998 Jun; 149(6):631-6. PubMed ID: 9611102
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists.
Lasheras B; Berjón A; Montañés R; Roca J; Romero G; Ramírez MJ; Del Río J
Arzneimittelforschung; 1996 Apr; 46(4):401-6. PubMed ID: 8740088
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
30. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
Tremblay PB; Kaiser R; Sezer O; Rosler N; Schelenz C; Possinger K; Roots I; Brockmoller J
J Clin Oncol; 2003 Jun; 21(11):2147-55. PubMed ID: 12775740
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
[TBL] [Abstract][Full Text] [Related]
32. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
33. [A new antiemetic ramosetron hydrochloride].
Tsukagoshi S
Gan To Kagaku Ryoho; 1997 Feb; 24(3):371-80. PubMed ID: 9051143
[TBL] [Abstract][Full Text] [Related]
34. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology and preclinical antiemetic properties of ondansetron.
Tyers MB
Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
[TBL] [Abstract][Full Text] [Related]
36. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
37. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
39. [Serotonin and anticancer drug-induced emesis].
Minami M; Endo T; Hamaue N; Hirafuji M
Yakugaku Zasshi; 2004 Aug; 124(8):491-507. PubMed ID: 15297719
[TBL] [Abstract][Full Text] [Related]
40. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
